Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 17/20 | 0.78 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.78 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.59 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.59 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.57 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437926 | 0.99 | HRH3 (0.81) | HRH3KCNH2ALDH1A1GAAMAPT | |
| Hydrochloric Acid SCHEMBL3569842 | 0.99 | HRH3 (0.76) | HRH3KCNH2ALDH1A1GAAMAPT | |
| SCHEMBL3584179 | 0.99 | HRH3 (0.81) | HRH3KCNH2ALDH1A1GAAMAPT | |
| SCHEMBL3573919 | 0.99 | HRH3 (0.81) | HRH3KCNH2ALDH1A1GAAMAPT | |
| SCHEMBL3580274 | 0.97 | HRH3 (0.78) | HRH3KCNH2ALDH1A1GAAMAPT | |
| SCHEMBL3576424 | 0.95 | HRH3 (0.79) | HRH3KCNH2ALDH1A1GAAMAPT | |
| SCHEMBL23855510 | 0.90 | HRH3 (0.66) | HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL23855511 | 0.88 | HRH3 (0.64) | HRH3KCNH2ALDH1A1HRH1HRH2 | |
| SCHEMBL23855522 | 0.86 | HRH3 (0.65) | HRH3KCNH2ALDH1A1HRH1HRH2 | |
| SCHEMBL21659286 | 0.86 | HRH3 (0.66) | HRH3KCNH2ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | claimed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | claimed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | disclosed |
| EP-1313721-B1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1313721-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065278-A1 | Non-imidazole aryloxyalkylamines | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885GAA 641/4885 |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | HRH4, HRH3, HRH2 | HRH3 2/4885KCNH2 1178/4885GAA 3063/4885 |
| US-20100004241-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885GAA 641/4885 |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | HRH3 3/4885KCNH2 470/4885GAA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.